The U.S. Food and Drug Administration authorized a blood test for Alzheimer’s disease developed by Roche and Eli Lilly in July 2026 [1, 2].
This authorization provides a less invasive alternative to traditional diagnostics. By reducing reliance on costly imaging or painful procedures, the test can speed referrals to neurologists for patients experiencing cognitive impairment.
The test targets adults 55 years and older [1]. It works by measuring the protein p-tau217 to detect early signs of the disease [1, 2, 3]. According to data from the developers, the test offers a sensitivity close to 90% [1].
Research into the p-tau217 biomarker suggests significant predictive capabilities. Some data indicates that elevated levels of the protein are associated with a 38% higher probability of early dementia within five years [4]. Other reports suggest the blood analysis can predict the risk of developing Alzheimer's up to 10 years in advance [5].
While the FDA authorization focuses on the U.S. market, the test is being marketed by the Swiss company Roche and the U.S.-based Eli Lilly [1, 6]. Accessibility varies by region; for example, the cost of the test in Mexico is reported to be approximately 20,000 pesos [6].
The shift toward blood-based biomarkers represents a move away from cerebrospinal fluid draws and PET scans. These traditional methods are often expensive, and can be invasive for elderly patients.
“The test offers a sensitivity close to 90%.”
The authorization of a high-sensitivity blood test shifts Alzheimer's diagnosis from reactive confirmation to proactive screening. By identifying biomarkers like p-tau217 years before severe symptoms appear, healthcare providers can implement supportive care and clinical trials earlier. However, the disparity in pricing and availability, as seen in international markets, suggests that the benefit of early detection may initially be limited by socioeconomic factors.
